UnitedHealth Group Inc (UNH) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

UnitedHealth Group Inc (UNH)

397.14

-3.80 (0.95%)

as of Sep 4, 2026, 8:00:00 pm Market Open.

289 watching

Investor Insights

Sep 6, 2026, 12:00 am

This summary was created by AI, based on 32 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) has seen mixed reviews from experts, with opinions fluctuating based on recent performance and external regulatory pressures. Some analysts express cautious optimism, noting that the company's fundamentals are improving and that it has potential for growth amid a challenging healthcare landscape. The return of the former CEO has sparked hope for effective cost management and operational improvements, potentially aiding in regaining investor confidence. However, there are concerns over high medical costs, regulatory scrutiny, and a turbulent political environment that could affect profitability. While some see opportunities for recovery and price appreciation, others highlight the risks associated with its reliance on Medicare funding and regulatory changes.

Consensus

Neutral

Valuation

Undervalued

Similar

CVS, CVS

BUY

Be ready for a lot of political noise leading up to the US election in Nov. 2020. UNH is a fantastic company. 170 million American hold private insurance through their employers. No, not all Americans, but they have coverage. UNH is well-positioned in health insurance.

WATCH

Owned it for five years until early this year, because of the noise of "medicare for all" that won't end until a Democratic candidate is chosen. An excellent company, but not timely.

TOP PICK

They report tomorrow. UnitedHealth the largest health insurer in the U.S. It has diversified operations. They acquired of pharmacy benefits manager, Catamaran, that'll give them competitive positioning. No matter who wins the next U.S. election, U.S. healthcare will still need UNH's business. (Analysts’ price target is $291.44)

TOP PICK

Names like this take time and are very volatile. It's weathered the storm and now spending time around $2.30. It's ready to go back up with strong momentum perhaps over 5 weeks. (Analysts’ price target is $288.52)

TOP PICK

The US is talking about having Medicare for all. This company does a good job of eliminating cost for all involved. They raised the dividend over the last few years. He sees it as a good solid company. (Analysts’ price target is $287.80)

PAST TOP PICK

(A Top Pick Mar 11/19, Up 2%) Really good day trade. Not a happy place to be as a retail investor. Not something you need to own right away. Chart's gone straight up for so long, but now facing some turbulence. Now it's a hold or a watch.

TOP PICK

They are the largest Health Care provider in the US. He thinks it is going back into the $300 territory after the election. P/E is 17. (Analysts’ price target is $287.72)

DON'T BUY

Basically an insurance provider. Healthcare space in general is messy. Trump is attacking healthcare companies. Insurance costs are rising, but they can't keep going up when wages aren't increasing. So insurance is trying to move down the food chain. Plus, Amazon is getting into the business. He'd be really nervous.

TOP PICK

A managed care company. Like a large medical insurance company, but they own their own facilities and networks. A shock when it sold off. Valuation is fantastic. Once in a decade buying opportunity. Yield is 1.55%. (Analysts’ price target is $288.54)

BUY

Trading at 17 times forward earnings. 13-14% growth rate. 1.5% dividend yield. 15 billion dollar worth of free cash flow. They are in pharmacy and benefit management service. They are have scale across different segments. Good for an uncertain time despite the politics.

BUY ON WEAKNESS

Good operator. Sensible balance sheet. Like the "Home Depot" of healthcare. Difficult to buy on price. Well run. Always at a premium price, as it's a good company.

TOP PICK

Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.

WAIT

Start a position at $240? Positives: top-shelf management with a history of returning 50% of free cash flow each year through dividends and stock buys. They're massive and have cost advantage. Cons: in consolidation now. He takes a longer view on UNH, but wouldn't buy it now. There's no rush to. UNH is also beta. Numbers solid, but UNH isn't cheap. Watch it.

BUY

On a 12 months basis it is better than 85% of the companies in the NYSE. Healthcare has come back quite nicely. This is trading well above a rising 150 day average. This is a theme you can depend on. Managed Healthcare. Continue to hold it.

BUY ON WEAKNESS

It has characteristics of a defensive nature but grows at double digit earnings each year. There are headwinds in that space. Amazon may be entering the pharmacy business. But people are living longer and will need health care longer. Buy it on dips.

Showing 196 to 210 of 291 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

UnitedHealth Group Inc (UNH)